Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2024 11:48 ET | Source: Research and Markets

Analgesics Market Insights, Competitive Landscape and Market Forecast to 2030

Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Analgesics - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.The...
January 29, 2024 12:15 ET | Source: Research and Markets

MAXIGESIC IV Drug Insight and U.S. Market Forecasts to 2032: In-depth Product Overview, Regulatory Milestones, Competitive Landscape Analysis, and SWOT Analysis

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Dual Mode-of-Action...
October 18, 2023 01:00 ET | Source: Hyloris Pharmaceuticals SA

Hyloris annonce l’approbation de Maxigesic® IV par la FDA Américaine

Le puissant analgésique non opioïde Maxigesic® IV sera commercialisé aux États-Unis sous le nom de Combogesic® IVLes premières ventes aux États-Unis début de 2024 donneront lieu à un paiement d'étape...
October 18, 2023 01:00 ET | Source: Hyloris Pharmaceuticals SA

Hyloris announces U.S. FDA Approval of Maxigesic® IV

Maxigesic® IV, a potent non-opioid painkiller, to be marketed in the U.S. under the tradename Combogesic® IVFirst U.S. sales expected in early 2024, triggering a milestone payment of USD 2,1 million ...
April 18, 2023 01:00 ET | Source: Hyloris Pharmaceuticals SA

Hyloris annonce la soumission des données relatives au conditionnement de Maxigesic® IV demandées par la FDA aux Etats-Unis

- Données supplémentaires sur les substances extractibles et impuretés générées par un laboratoire accrédité situé en Amérique du Nord - Résultats analysés et évalués par des experts en toxicologie ...
April 18, 2023 01:00 ET | Source: Hyloris Pharmaceuticals SA

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for...